SCHEMBL6652224

SCHEMBL6652224

CCc1cc(-c2cccc(C#N)c2)n[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.52
LMNA P02545 2/20 0.50
CTSS P25774 1/20 0.49
CTSK P43235 1/20 0.49
USP30 Q70CQ3 1/20 0.47
CLK4 Q9HAZ1 2/20 0.44
XDH P47989 1/20 0.44
PGR P06401 1/20 0.43
HPGD P15428 2/20 0.43
CYP1A2 P05177 2/20 0.42
MAPK1 P28482 2/20 0.42
CYP2C19 P33261 2/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAOB P27338 1/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269506 0.83 L3MBTL1 (0.59) IDO1CTSSCTSKUSP30CLK4
SCHEMBL14985492 0.78 IDO1 (0.58) IDO1LMNACTSSCTSKCYP2C19
SCHEMBL14985490 0.78 IDO1 (0.50) IDO1LMNACTSSCTSKXDH
SCHEMBL1696565 0.77 L3MBTL1 (0.63) LMNACLK4CYP2C19CYP2D6LRRK2
SCHEMBL30250881 0.77 IDO1 (0.56) IDO1USP30CLK4XDHPGR
SCHEMBL16730757 0.77 MAPT (0.50) IDO1LMNAHPGDMAPK1CYP2C19
SCHEMBL16863148 0.77 IDO1 (0.56) IDO1USP30CLK4XDHPGR
SCHEMBL3344891 0.77 METAP2 (0.49) LMNAHPGDCYP2C19ALDH1A1KDM4E
SCHEMBL14985496 0.77 ALDH1A1 (0.50) IDO1LMNACTSSCTSKPGR
SCHEMBL14985517 0.76 POLB (0.64) IDO1LMNAUSP30CLK4XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788086-B1 SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS BOEHRINGER INGELHEIM INT (DE) 2016-10-12 EP disclosed
WO-2013083591-A1 SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 WO disclosed
US-20130143870-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-06 US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143870-A1 NOVEL COMPOUNDS GRM5, GRM1, GRIK5 IDO1 3659/4885LMNA 4743/4885CTSS 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.